Immune checkpoint inhibitors have been shown to enhance the outcomes of CD19 CAR T-cell therapies for children with relapsed B-ALL and are now entering the arena of adult B-ALL treatments. This evidence concerns the gene CD19 and precursor B-cell acute lymphoblastic leukemia.